<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="0" ids="29108">Ca2+</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> flunarizine (Flunarl) was administered to 14 patients (4 men and 10 women, 70.9 +/- 2.5 years old, mean +/- S.E.), suffering from cerebral <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The dose was 10 mg/day given for 8 weeks and the following results were obtained </plain></SENT>
<SENT sid="2" pm="."><plain>The volume flow of the common carotid artery was increased in the 4th week after the administration, and this increase was maintained until the 8th week </plain></SENT>
<SENT sid="3" pm="."><plain>Flunarizine caused improvement of peripheral hemodynamics, induced inhibition of platelet aggregation and improvement erythrocyte deformability </plain></SENT>
<SENT sid="4" pm="."><plain>These results indicate that the <z:chebi fb="0" ids="29108">Ca2+</z:chebi> entry blocker flunarizine improves cerebral and peripheral hemodynamics including microcirculation by inhibiting platelet aggregation and erythrocyte deformability </plain></SENT>
</text></document>